Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Fiche publication
Date publication
janvier 2021
Journal
Journal of Crohn's & colitis
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ
Lien Pubmed
Résumé
Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind, placebo-controlled trial in adults with moderately-to-severely active ulcerative colitis (OASIS), etrasimod 2 mg provided significant benefit versus placebo and was generally well tolerated. This open-label extension (OLE) evaluated safety and efficacy of etrasimod for up to 52 weeks.
Mots clés
Etrasimod, Long-term extension study, Ulcerative colitis
Référence
J Crohns Colitis. 2021 Jan 21;: